Before gumarontinib, savolitinib was the first MET inhibitor approved in China for treating metastatic NSCLC with METex14 skipping alterations in patients who have progressed after or who are unable to tolerate platinum-based chemotherapy (National medical products administration, 2021). The gene discussed is MET; the disease is non-small cell lung carcinoma.